Get the Stockscreener App
110.86
1.17%
1.28
After Hours:
110.79
-0.07
-0.06%
Novartis Ag Adr stock is traded at $110.86, with a volume of 1.58M.
It is up +1.17% in the last 24 hours and down -1.21% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$109.58
Open:
$109.57
24h Volume:
1.58M
Relative Volume:
0.66
Market Cap:
$216.19B
Revenue:
$51.72B
Net Income/Loss:
$11.94B
P/E Ratio:
18.85
EPS:
5.88
Net Cash Flow:
$13.81B
1W Performance:
+7.21%
1M Performance:
-1.21%
6M Performance:
-4.85%
1Y Performance:
+19.10%
1-Day Range:
$109.50
$111.27
1-Week Range:
$104.69
$111.27
52-Week Range:
$92.35
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | UBS | Buy → Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Underweight |
| Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
| Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
| Dec-05-22 | Upgrade | Stifel | Hold → Buy |
| Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
| Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-22-21 | Initiated | Bernstein | Mkt Perform |
| Mar-10-21 | Downgrade | Argus | Buy → Hold |
| Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Sep-10-20 | Upgrade | UBS | Neutral → Buy |
| Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
| Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
| May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
| May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jan-25-18 | Reiterated | Leerink Partners | Outperform |
| Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Huntington's Disease Treatment Market to Hit $2.03 Billion by 2033, Driven by Cutting-Edge Therapies - GlobeNewswire Inc.
Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com
Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com
FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com
Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
No room on the ARK? - Morningstar
5 Large Drug Stocks To Watch As Industry Recovers - Barchart
FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart
Novartis scraps use of diverse panels for hires in US - Reuters
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart
Giovanni Caforio, M.D. - Novartis
Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily
META_TITLE_QUOTE - Yahoo Finance
Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance
AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com
NVS Quantitative Stock Analysis - Nasdaq
Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha
Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart
Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors UK
Novartis 2017 Financial Results - Novartis
ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily
Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily
Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily
NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News
Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online
HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise
Novartis's SWOT analysis: pharma giant's stock navigates generic headwinds - Investing.com
Novartis Earnings: Results In-Line; Growth Brands to Offset Entresto Loss of Exclusivity in 2025 - Morningstar
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.01%
1.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):